October PharmaE Past Earnings Performance
Past criteria checks 4/6
October PharmaE has been growing earnings at an average annual rate of 33.2%, while the Pharmaceuticals industry saw earnings growing at 5.8% annually. Revenues have been growing at an average rate of 15.7% per year. October PharmaE's return on equity is 30.9%, and it has net margins of 14.9%.
Key information
33.2%
Earnings growth rate
33.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 9.8% |
| Revenue growth rate | 15.7% |
| Return on equity | 30.9% |
| Net Margin | 14.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How October PharmaE makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,012 | 150 | 171 | 0 |
| 30 Sep 23 | 891 | 131 | 165 | 0 |
| 31 Mar 23 | 761 | 114 | 150 | 0 |
| 31 Dec 22 | 727 | 114 | 142 | 0 |
| 30 Sep 22 | 709 | 114 | 138 | 0 |
| 31 Mar 22 | 669 | 114 | 130 | 0 |
| 31 Dec 21 | 655 | 120 | 124 | 0 |
| 30 Sep 21 | 651 | 123 | 125 | 0 |
| 30 Jun 21 | 619 | 131 | 108 | 0 |
| 31 Mar 21 | 589 | 121 | 100 | 0 |
| 31 Dec 20 | 543 | 88 | 105 | 0 |
| 30 Sep 20 | 527 | 79 | 100 | 0 |
| 30 Jun 20 | 527 | 62 | 110 | 0 |
| 31 Mar 20 | 529 | 38 | 117 | 0 |
| 31 Dec 19 | 523 | 34 | 113 | 0 |
| 30 Sep 19 | 499 | 17 | 109 | 0 |
| 30 Jun 19 | 462 | 8 | 103 | 0 |
| 31 Mar 19 | 426 | 18 | 90 | 0 |
| 31 Dec 18 | 401 | 18 | 89 | 0 |
| 30 Sep 18 | 355 | 21 | 83 | 0 |
| 30 Jun 18 | 339 | 25 | 91 | 0 |
| 31 Mar 18 | 346 | 34 | 100 | 0 |
| 31 Dec 17 | 350 | 45 | 99 | 0 |
| 30 Sep 17 | 351 | 52 | 112 | 0 |
| 30 Jun 17 | 337 | 50 | 104 | 0 |
| 31 Mar 17 | 302 | 42 | 95 | 0 |
| 31 Dec 16 | 288 | 35 | 95 | 0 |
| 30 Sep 16 | 266 | 24 | 85 | 0 |
| 30 Jun 16 | 256 | 19 | 87 | 0 |
| 31 Mar 16 | 258 | 20 | 87 | 0 |
| 31 Dec 15 | 244 | 16 | 84 | 0 |
| 30 Sep 15 | 239 | 22 | 76 | 0 |
| 30 Jun 15 | 231 | 17 | 78 | 0 |
| 31 Mar 15 | 214 | 10 | 76 | 0 |
| 31 Dec 14 | 202 | 8 | 71 | 0 |
| 30 Sep 14 | 203 | 10 | 74 | 0 |
| 30 Jun 14 | 196 | 13 | 64 | 0 |
| 31 Mar 14 | 202 | 16 | 64 | 0 |
| 31 Dec 13 | 200 | 18 | 61 | 0 |
| 30 Sep 13 | 183 | 5 | 68 | 0 |
| 30 Jun 13 | 179 | 0 | 64 | 0 |
Quality Earnings: OCPH has high quality earnings.
Growing Profit Margin: OCPH's current net profit margins (14.9%) are lower than last year (15.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OCPH's earnings have grown significantly by 33.2% per year over the past 5 years.
Accelerating Growth: OCPH's earnings growth over the past year (32.2%) is below its 5-year average (33.2% per year).
Earnings vs Industry: OCPH earnings growth over the past year (32.2%) exceeded the Pharmaceuticals industry 27.9%.
Return on Equity
High ROE: OCPH's Return on Equity (30.9%) is considered high.